Cellastra Revenue and Competitors

Cellastra Inc., a developer of proprietary gene and cell therapies, is a private biotech company based in the San Francisco Financial District. It was founded and managed by proven industry executives. Cellastra’s mission is to develop Disruptive, First or Best in Class Gene and Cell Therapies addressing global unmet needs: Our current portfolio includes proprietary recombinant AAV6 gene vector mediated intervention where the aim of gene transfer is to transfect and program cells in the wound area after surgery (CELLEXA) or in the upper respiratory area during a pandemic: (COVVEXA): CELLEXA: For n vivo production of a natural anti-scarring peptide, already found safe and effective in preclinical and clinical Phase 2 proof of concept studies) throughout the wound healing process. The vector may be applied as a onetime treatment under the skin before wound closure after surgery. COVVEXA: . A proprietary recombinant AAV6 gene vector mediated intervention where the aim of gene transfer is to transfect and program cells in the upper respiratory tract for n vivo production of a natural bioactive peptide with demonstrated anti-infective, anti-inflammatory and anti-thrombotic effects for months throughout a pandemic. The aim of the gene transfer are 1) to block heparin sulphat docking stations and ACE-2 receptors, 2) to fight COVID-19 or other viral, bacterial or fungal infections, 3) to counteract / prevent excessive upregulation of cytokines (“cytokine storm”), and 4) to prevent formation of fibrin plugs or micro thromboembolism by counteract / prevent excessive upregulation prothrombotic plasminogen activator inhibitors (PAI) throughout a pandemic. The vector may be applied as a onetime inhaled (or intra nasal) dosing to prevent COCID-19 or its com0plications.